China Mobile Limited (NYSE:CHL) shares fell -0.11% in last trading session and ended the day at $54.29. CHL Gross Margin is 81.60% and its has a return on assets of 17.80%. China Mobile Limited (NYSE:CHL) quarterly performance is -5.43%.
China Mobile Ltd. (NYSE:CHL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, MarketBeat.com reports.
Cisco Systems, Inc. (NASDAQ:CSCO) shares fell -0.21% in last trading session and ended the day at $27.90. CSCO Gross Margin is 61.50% and its has a return on assets of 9.30%. Cisco Systems, Inc. (NASDAQ:CSCO) quarterly performance is 2.62%.
On 25 March, Cisco Systems, Inc. (NASDAQ:CSCO) completed its $1.4 billion acquisition of Jasper Technologies, bringing the fast-growing smaller company into Cisco’s new Internet of Things (IoT) Cloud Business unit.
Oracle Corporation (NYSE:ORCL) caters to the Technology space. It has a net profit margin of 23.80% and weekly performance is -2.07%. On the last day of trading company shares ended up at $40.62. Oracle Corporation (NYSE:ORCL) distance from 50-day simple moving average (SMA50) is 9.94%.
On 23 March, Oracle Corporation (NYSE:ORCL) has unveiled plans to set up a state-of-the-art campus centered in Bengaluru, India’s IT capital.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shares fell -7.95% in last trading session and ended the day at $38.31. IONS Gross Margin is 1.80% and its has a return on assets of -9.10%.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that a jury in the United States District Court, Northern District of California found in favor of Merck and Ionis in a patent dispute related to Gilead’s sofosbuvir-based medicines for the treatment of hepatitis C virus (HCV), including Sovaldi and Harvoni.
ADMA Biologics, Inc. (NASDAQ:ADMA) caters to the Healthcare space. Its weekly performance is 33.51%. On the last day of trading company shares ended up at $7.73. ADMA Biologics, Inc. (NASDAQ:ADMA) distance from 50-day simple moving average (SMA50) is -201.20%.
ADMA Biologics, Inc. (NASDAQ:ADMA) announced its financial results for the year ended December 31, 2015, and outlined the company’s 2015 accomplishments and anticipated milestones for 2016. The consolidated net loss for the year ended December 31, 2015 was $18.0 million, or $(1.73) per share, as compared to a consolidated net loss of $16.8 million, or ($1.81) per share for the year ended December 31, 2014.
Leave a Reply